AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16460314 — intervention group
Group type: EXPERIMENTAL
Intervention: zeaxanthin (OPTISHARP) and/or lutein supplementation
Number of subjects: 24
Study 14722336 — intervention group
Group type: EXPERIMENTAL
Intervention: active multicomponent counseling and support intervention
Number of subjects: 406
Study 14722336 — intervention group
Group type: COMPARATOR
Intervention: usual care condition
Number of subjects: 406
Study 11464310 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg daily for 3 weeks
Number of subjects: 33
Study 11464310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 9876078 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal sclerotherapy (1 or 2 sessions)
Number of subjects: 162
Study 9876078 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal excision of the prolapsing mucosa
Number of subjects: 162
Study 7864609 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's behavioral neophobia levels
Number of subjects: 0
Study 7864609 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's and parents' behavioral and trait neophobia scores
Number of subjects: 0
Study 7864609 — intervention group
Group type: COMPARATOR
Intervention: Parents' neophobia with respect to foods of animal origin
Number of subjects: 0
Study 2563616 — intervention group
Group type: EXPERIMENTAL
Intervention: Grenz ray therapy (5 Gy applied on 10 occasions at intervals of 1 week)
Number of subjects: 22
Study 2563616 — intervention group
Group type: COMPARATOR
Intervention: Simulated therapy (control)
Number of subjects: 22
Study 799988 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (Tofranil) added to standard analgesic anti-rheumatic therapy
Number of subjects: 65
Study 799988 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (Tofranil)
Number of subjects: 65
Study 799988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 30391714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet snack consumed post-dinner (19:30)
Number of subjects: 17
Study 30391714 — intervention group
Group type: COMPARATOR
Intervention: Sweet snack consumed mid-afternoon (15:30)
Number of subjects: 17
Study 27932679 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (ibuprofen 1,200 mg/day)
Number of subjects: 19
Study 27932679 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plc)
Number of subjects: 19
Study 25646876 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging (eGEMs) three times per week for 12 weeks
Number of subjects: 269
Study 25646876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 269
Study 24228747 — intervention group
Group type: EXPERIMENTAL
Intervention: SSPANLI intervention (pedometer-based physical activity promotion and nutrition education)
Number of subjects: 106
Study 24228747 — intervention group
Group type: COMPARATOR
Intervention: Usual non-surgical care (control group)
Number of subjects: 106
Study 22124225 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-millisecond brief pulse ECT
Number of subjects: 22
Study 22124225 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3-millisecond ultrabrief pulse ECT
Number of subjects: 22
Study 22124225 — intervention group
Group type: COMPARATOR
Intervention: Comparison of brief pulse ECT vs ultrabrief pulse ECT
Number of subjects: 22
Study 19118724 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol
Number of subjects: 80
Study 19118724 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 80
Study 16729788 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (4 mg tablet)
Number of subjects: 51
Study 16729788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 15589861 — intervention group
Group type: EXPERIMENTAL
Intervention: urinary FSH (u-FSH)
Number of subjects: 34
Study 15589861 — intervention group
Group type: COMPARATOR
Intervention: recombinant FSH (r-FSH)
Number of subjects: 34
Study 11356893 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation over muscles that plantarflex the ankle (1 msec pulses, 100 Hz)
Number of subjects: 5
Study 9215520 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session ('skills' group - low-intensity) intervention
Number of subjects: 333
Study 9215520 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-session ('practice' group - high intensity) intervention
Number of subjects: 333
Study 9215520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention groups
Number of subjects: 333
Study 8025136 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery (CABG) using internal mammary artery as conduit for revascularization
Number of subjects: 0
Study 8025136 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study 8025136 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 0
Study 3111354 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg enoxacin
Number of subjects: 155
Study 3111354 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg enoxacin
Number of subjects: 155
Study 3111354 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 155
Study 28885287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracing (rigid thoracolumbosacral orthosis, worn 23 hours/day)
Number of subjects: 53
Study 28885287 — intervention group
Group type: COMPARATOR
Intervention: Exercise (Scientific Exercise Approach to Scoliosis)
Number of subjects: 53
Study 28139405 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib (150 mg orally twice daily) in combination with bendamustine and rituximab
Number of subjects: 416
Study 28139405 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with bendamustine and rituximab
Number of subjects: 416
Study 28139405 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib
Number of subjects: 416
Study 28139405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 25141012 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological sleep extension
Number of subjects: 125
Study 24346676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional guidelines and educational program for school lunch cooks
Number of subjects: 20
Study 24346676 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 20
Study 20507568 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspinous implant surgery
Number of subjects: 0
Study 20507568 — intervention group
Group type: COMPARATOR
Intervention: Bony decompression surgery
Number of subjects: 0
Study 18790154 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 0
Study 18790154 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal excision using endoscopic microsurgery
Number of subjects: 0
Study 18790154 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic‐assisted laparoscopic surgery
Number of subjects: 0
Study 18790154 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive treatment for rectal cancer
Number of subjects: 0
Study 16263817 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.4 mg testosterone gel
Number of subjects: 26
Study 16263817 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.8 mg testosterone gel
Number of subjects: 26
Study 16263817 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.2 mg testosterone gel
Number of subjects: 26
Study 16263817 — intervention group
Group type: COMPARATOR
Intervention: 0 mg testosterone gel
Number of subjects: 26
Study 16263817 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of testosterone gel
Number of subjects: 26
Study 12684146 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing with nonoxynol‐9 co-medication
Number of subjects: 12
Study 12684146 — intervention group
Group type: COMPARATOR
Intervention: NuvaRing without nonoxynol‐9
Number of subjects: 12
Study 11027905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg/kg
Number of subjects: 10
Study 11027905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.50 mg/kg
Number of subjects: 10
Study 11027905 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 10
Study 8816645 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2, 3.5, and 4.5-millimeter cortical-bone screws; 3.5-millimeter cancellous-bone screw; 3.5-millimeter self-tapping screw with bicortical purchase
Number of subjects: 12
Study 8816645 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5-millimeter self-tapping screw with unicortical or bicortical purchase
Number of subjects: 12
Study 8156509 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic peritoneal perfusion (CHPP) with 10 micrograms/ml mitomycin C
Number of subjects: 82
Study 8156509 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CHPP)
Number of subjects: 82
Study 8156509 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic peritoneal perfusion (CHPP)
Number of subjects: 82
Study 3168696 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-sensitive enteric-coated pancreatic enzyme preparation
Number of subjects: 8
Study 3168696 — intervention group
Group type: COMPARATOR
Intervention: Conventional enzyme preparations
Number of subjects: 8
Study 31710134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing case management (includes nursing consultations, telephone contact, home visits, health education, and appropriate referrals)
Number of subjects: 94
Study 31710134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing case management
Number of subjects: 94
Study 30033855 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dysmenorrhea and nonmenstrual pelvic pain impact items
Number of subjects: 0
Study 28138971 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabis administration (6.9% [50.4 mg] THC)
Number of subjects: 0
Study 28138971 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.001% THC)
Number of subjects: 0
Study 26261389 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block (Group I, n=62)
Number of subjects: 123
Study 26261389 — intervention group
Group type: COMPARATOR
Intervention: Caudal block (Group II, n=61)
Number of subjects: 123
Study 24059116 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS treatment for 2 weeks (15 days) combined with selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 159
Study 24059116 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant treatment (SSRI) only
Number of subjects: 159
Study 24059116 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (group C)
Number of subjects: 159
Study 21868346 — intervention group
Group type: EXPERIMENTAL
Intervention: Trsatuzumab (Herceptin) combined with FOLFIRI regimen (irinotecan plus 5‐FU/LV)
Number of subjects: 34
Study 21868346 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI regimen alone
Number of subjects: 34
Study 18974308 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (cognitive behavioral therapy + sertraline)
Number of subjects: 488
Study 18974308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 488
Study 18974308 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (up to 200 mg per day)
Number of subjects: 488
Study 18974308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 488
Study 18974308 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 488
Study 18974308 — intervention group
Group type: EXPERIMENTAL
Intervention: All therapies
Number of subjects: 488
Study 16832415 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic nurse counsellor
Number of subjects: 586
Study 16832415 — intervention group
Group type: COMPARATOR
Intervention: Clinical geneticist (current service)
Number of subjects: 586
Study 12892241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic lumbar stabilization exercises
Number of subjects: 42
Study 12892241 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise programme
Number of subjects: 42
Study 12892241 — intervention group
Group type: COMPARATOR
Intervention: No exercises (Control group)
Number of subjects: 42
Study 10852274 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. clodronate 300 mg daily for 10 consecutive days
Number of subjects: 32
Study 10852274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7486185 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 60
Study 7486185 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 60
Study 2307806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 27
Study 2307806 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower concentrations of sucrose
Number of subjects: 27
Study 2307806 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of sucrose
Number of subjects: 27
Study 6784264 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study 6784264 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8
Study 6784264 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 8
Study 6784264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6784264 — intervention group
Group type: EXPERIMENTAL
Intervention: All active drugs (Propranolol, Atenolol, Metoprolol)
Number of subjects: 8
Study 6784264 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs (including placebo)
Number of subjects: 8
Study 31081475 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial analgesia
Number of subjects: 389
Study 31081475 — intervention group
Group type: COMPARATOR
Intervention: No neuraxial analgesia (Control)
Number of subjects: 389
Study 28471950 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified MSLT performed in the unattended home
Number of subjects: 34
Study 28471950 — intervention group
Group type: COMPARATOR
Intervention: Modified MSLT performed in the hospital
Number of subjects: 34
Study 25547112 — intervention group
Group type: EXPERIMENTAL
Intervention: computer‐generated interactive visual feedback training
Number of subjects: 12
Study 25547112 — intervention group
Group type: COMPARATOR
Intervention: mirror visual feedback training
Number of subjects: 12
Study 23398944 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d lutein
Number of subjects: 117
Study 23398944 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d lutein
Number of subjects: 117
Study 23398944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 21290392 — intervention group
Group type: EXPERIMENTAL
Intervention: 940 nm laser treatment (GR1)
Number of subjects: 23
Study 21290392 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical PA agent indocyanine-green followed by 810 nm laser treatment (GR2)
Number of subjects: 23
Study 19118130 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed Constraint-Induced Therapy (CIT)
Number of subjects: 60
Study 19118130 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Arm Training (BAT)
Number of subjects: 60
Study 19118130 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 60
Study 17185355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 15
Study 17185355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15503853 — intervention group
Group type: EXPERIMENTAL
Intervention: Persica mouthwash
Number of subjects: 28
Study 15503853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11471604 — intervention group
Group type: EXPERIMENTAL
Intervention: Small bowel enema (SBE)
Number of subjects: 244
Study 11471604 — intervention group
Group type: COMPARATOR
Intervention: Barium follow-through (FT)
Number of subjects: 244
Study 9770738 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60-90 mg 4 times a day)
Number of subjects: 17
Study 9770738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20-30 mg 4 times a day)
Number of subjects: 17
Study 9770738 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (single dose)
Number of subjects: 17
Study 9770738 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (single dose)
Number of subjects: 17
Study 9770738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (long-term treatment)
Number of subjects: 17
Study 9770738 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (long-term treatment)
Number of subjects: 17
Study 7885111 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous stem cell support
Number of subjects: 33
Study 7885111 — intervention group
Group type: COMPARATOR
Intervention: Standard dose chemotherapy
Number of subjects: 33
Study 2593192 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ventilation
Number of subjects: 28
Study 2593192 — intervention group
Group type: COMPARATOR
Intervention: Transport ventilator
Number of subjects: 28
Study 1092033 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine hydrochloride
Number of subjects: 26
Study 1092033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 30658935 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-driven treatment (ABVD after positive PET2 or BEACOPPescalated after negative PET2)
Number of subjects: 823
Study 30658935 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (BEACOPPescalated for all cycles)
Number of subjects: 823
Study 30658935 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-driven treatment (ABVD after positive PET2)
Number of subjects: 823
Study 30658935 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-driven treatment
Number of subjects: 823
Study 30658935 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 823
Study 24659024 — intervention group
Group type: EXPERIMENTAL
Intervention: Airex® pad training (intervention group)
Number of subjects: 11
Study 24659024 — intervention group
Group type: COMPARATOR
Intervention: Control group (without the pad)
Number of subjects: 11
Study 22584456 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive telephone coaching and electronic contact (ATC) with the Loozit group program (n=73)
Number of subjects: 151
Study 22584456 — intervention group
Group type: COMPARATOR
Intervention: Loozit group program alone (n=78)
Number of subjects: 151
Study 21414746 — intervention group
Group type: EXPERIMENTAL
Intervention: All-polyethylene tibial component
Number of subjects: 47
Study 21414746 — intervention group
Group type: COMPARATOR
Intervention: Metal-backed modular version of the implant
Number of subjects: 47
Study 19001014 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention group (N = 249)
Number of subjects: 491
Study 19001014 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (N = 242)
Number of subjects: 491
Study 16761192 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (0.5 mg)
Number of subjects: 32
Study 14726225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trials with six subjects
Number of subjects: 6
Study 11131210 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum HF-6700 oxygenator
Number of subjects: 20
Study 11131210 — intervention group
Group type: COMPARATOR
Intervention: HF-5700 oxygenator
Number of subjects: 20
Study 9339113 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (500 mg/kg for >1500 g, 700 mg/kg for <1500 g) on days 1, 2, and 8
Number of subjects: 80
Study 9339113 — intervention group
Group type: COMPARATOR
Intervention: Control (no IVIG)
Number of subjects: 80
Study 9339113 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 80
Study 8408940 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 160
Study 8408940 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 160
Study 8408940 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Resistance - Positive Expiratory Pressure (IR-PEP)
Number of subjects: 160
Study 3158273 — intervention group
Group type: COMPARATOR
Intervention: Standard breakfast (B)
Number of subjects: 10
Study 3158273 — intervention group
Group type: COMPARATOR
Intervention: Bioassay measurement
Number of subjects: 10
Study 29661678 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg kg‐1; group PP)
Number of subjects: 32
Study 29661678 — intervention group
Group type: COMPARATOR
Intervention: Saline (group CP)
Number of subjects: 32
Study 29661678 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (1.3 mg kg‐1 minute‐1; group SI)
Number of subjects: 32
Study 27621264 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive local anesthesia combined with general anesthesia (Group A)
Number of subjects: 80
Study 27621264 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive local anesthesia combined with spinal anesthesia (Group B)
Number of subjects: 80
Study 27621264 — intervention group
Group type: COMPARATOR
Intervention: Placebo with general anesthesia (Group C)
Number of subjects: 80
Study 27621264 — intervention group
Group type: COMPARATOR
Intervention: Placebo with spinal anesthesia (Group D)
Number of subjects: 80
Study 27621264 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive local anesthesia (Groups A and B)
Number of subjects: 80
Study 24309022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (100 million CFU/day)
Number of subjects: 400
Study 24309022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 21431100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 0
Study 21431100 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 0
Study 19020919 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (600 mg vitamin E and 1,000 mg vitamin C daily)
Number of subjects: 34
Study 19020919 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (3x/week)
Number of subjects: 34
Study 19020919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 17234902 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastase
Number of subjects: 269